No Data
No Data
Teyi Pharmaceutical Group (002728.SZ) continues to increase its marketing efforts for high-potential products such as Skin Disease Xue Du Wan and Blood Sugar Reducing Shu Wan with a large market capacity.
On August 6th, Gelunhui reported that Teyi Pharmaceutical Group (002728.SZ) stated in an investor relations activity that in order to enhance the company's core competitiveness, the management continues to increase the market promotion efforts of potential varieties such as Skin Disease and Blood Toxin Pills and Hypoglycemic Comfort Pills with large market capacity based on the sales promotion of Zhikebao Tablets. Currently, the market feedback of the Skin Disease and Blood Toxin Pills and Hypoglycemic Comfort Pills two potential varieties is good. Against the backdrop of strong support from national industrial policies for the development of traditional Chinese medicine industry, and given the large market potential of the Skin Disease and Blood Toxin Pills and Hypoglycemic Comfort Pills, the company has cultivated the above varieties as major varieties after Zhikebao Tablets.
We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt
Teyi Pharmaceutical Group (002728.SZ) has repurchased 2.25% of its shares.
On August 1st, Gelonhui reported that Te Yi Pharmaceutical Group (002728.SZ) repurchased 11,514,584 shares of the company through the Shenzhen Stock Exchange trading system by centralized bidding trading until July 31, 2024. The repurchased shares account for 2.25% of the company's current total share capital. The highest price of the repurchase transaction was 8.03 yuan/share and the lowest price was 7.07 yuan/share. The total amount paid for the repurchase was 85,060,077.64 yuan (excluding relevant transaction fees). The source of funds for this share repurchase was the company's own funds, and the repurchase price did not exceed the price set in the repurchase plan.
Teyi Pharmaceutical Group (002728.SZ): Repurchased 2.25% of its shares.
On July 29th, Gelunhui reported that teyi pharmaceutical group (002728.SZ) repurchased 11,514,584 shares of the company through the Shenzhen Stock Exchange trading system by centralized bidding trading method as of July 29th, 2024, accounting for 2.25% of the total share capital of the company. The highest and lowest prices of the repurchase transaction were 8.03 yuan/share and 7.07 yuan/share respectively. The total amount paid was RMB 85,060,077.64 (excluding relevant transaction costs).
Teyi Pharmaceutical Group: Summary of Half-Year Report in 2024.
Teyi Pharmaceutical Group: Half-year report for the year 2024.
No Data